CDH2 and cancer: The EMT of cancer cells is characterized by a downregulation of epithelial markers such as E-cadherin, α-cadherin, and γ-cadherin and acquisition of a mesenchymal phenotype, accompanied by upregulation of periostin, vimentin, fibronectin and N-cadherin.